Fig. 6. VP1/CRA vaccine could induce the antigen-specific antitumor effect.

a Treatment schedule was depicted. Naive BALB/c mice were subcutaneously inoculated with CMS5-VP1, CMS5, or 4T1 tumor cells at 1 × 10⁶ per mouse with five mice per group on day 0. When tumors were palpable, tumor-bearing mice were vaccinated in the left hind limp thrice with 1-week intervals starting from day 5. b Tumors were measured with digital calipers every 3 days and tumor volumes were calculated. Mice were euthanized when tumor volumes reached 2000 mm³ or when tumors began to impair mobility or ulcerate.